FLASHNEWS:

Pharma Sector Faces Revenue Decline Amid Export Challenges

Karachi: A recent report on the pharmaceutical sector has revealed a 1% year-on-year revenue decline for a sample of nine companies in the third quarter of calendar year 2026, alongside a 5% year-on-year growth in cumulative earnings. These figures highlight the ongoing challenges faced by the industry, particularly in terms of exports.

According to JS Global, the sector experienced a 12% year-on-year increase and an 8% quarter-on-quarter growth in revenue based on industry data. However, the sample of listed companies reported a contrasting 1% year-on-year decline and a 6.3% quarter-on-quarter growth in top-line revenue. This discrepancy is attributed to higher trade discounts and disrupted exports to Afghanistan. Exports via land have been stalled since October 2025 and air routes have been unavailable since April 2026, prompting companies to seek alternative markets, though the geopolitical tensions in the Middle East present ongoing difficulties.

The FY27 Federal Budget introduced several policy measures favorable to the sector, including relief for the salaried class, a 2-percentage-point reduction in super tax for corporations, and reduced duties on Active Pharmaceutical Ingredients, specifically for cancer and contraceptive drugs. Despite these positive measures and stronger volumes and pricing, the sector's revenue remained nearly flat due to the high base from the previous year's exports to Afghanistan. Nonetheless, the long-term outlook for demand in the pharmaceutical sector is supported by Pakistan's demographic trends, which are expected to sustain pricing power.